ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA's stock price has experienced fluctuations and analyst adjustments over the past six months, with a 52-week high of $28.35 and a 52-week low of $13.40. Analyst ratings were adjusted by RBC Capital, HC Wainwright & Co., UBS, Citigroup, Stifel and Mizuho. The U.S. launch of DAYBUE® STIX began on a limited basis in Q1 2026, with a full launch planned for Q2 2026, and top-line results from the Phase 2 RADIANT study are anticipated between August and October 2026. In Q3 2025, ACADIA reported total revenues of $278.6 million, an 11% increase year-over-year. Director James M. Daly sold 30,000 shares of the company's stock on November 10, 2025, for a total of $671,100.00.

ACADIA Pharmaceuticals has noted some seasonality in the demand for its products, including typical seasonality at the beginning of the year and a seasonal reduction in gross to net from the Medicare Part D redesign in the first quarter of 2025. The company anticipates key metrics like unique patients served, bottle volumes, and net price to increase throughout the remainder of the year.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for neurological and CNS disorders and rare diseases, operating in the Health Technology sector. Its key commercial products include NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett Syndrome. The company's pipeline includes pimavanserin for other CNS conditions and remlifanserin for Alzheimer's disease psychosis, with Phase 2 results anticipated between August and October 2026. ACADIA also has an exclusive license to manufacture and produce the Trofinetide drug in North America from Neuren Pharmaceutical.

ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California, and primarily markets its products in the United States. It also has an operational presence in Denmark, Switzerland, and the UK.

ACADIA Pharmaceuticals emphasizes its commitment to addressing unmet medical needs in neurological disorders and rare diseases through scientific excellence and patient-centric development, focusing on improving the lives of patients and families. The FDA approval of DAYBUE® STIX in January 2026 is a positive development. In December 2023, ACADIA won a summary judgment in a patent suit related to Nuplazid.

ACADIA Pharmaceuticals Inc. has a significant institutional ownership presence, with 595 institutional owners holding a total of 190,254,225 shares. Major institutional shareholders include Baker Bros. Advisors Lp, BlackRock, Inc., and Vanguard Group Inc. Individual insiders hold approximately 0.516% of the shares.